Background: A bedside to bench to bedside approach entails starting with a clinical observation as the basis for research (bedside), unraveling its mechanism in the laboratory using preclinical models (bench), then translating mechanistic insights into the design of novel clinical trials (bedside). Objective: Discuss research based on three clinical observations in MS. 1) Disabilities differ between MS patients. 2) Pregnancy is protective in MS. 3) Sex differences occur in MS. Methods: 1) Disability-specific discovery used RiboTag technology to assess gene expression in the central nervous system (CNS) in a region-specific and cell-specific manner in a preclinical MS model, chronic experimental autoimmune encephalomyelitis (EAE) in C57BL/6 mice. A disability-specific biomarker for clinical trials was developed in MS using voxel based morphometry to map distinct clusters of gray matter atrophy that aligned with distinct disabilities.
Objectives: To longitudinally evaluate the utility of spinal cord atrophy measured from brain scans as a surrogate marker for impending conversion to secondary progressive MS (SPMS), in addition to brain measures. Methods: In a single center observational study, 57 of 507 RRMS subjects converted to SPMS during the 12-year observation period. Using demographic and clinical criteria, we matched them to 57 RRMS subjects who remained RRMS during the observation period. From brain MRI, we analyzed brain volumetrics and spinal cord area at C1 level over 12 years to evaluate their potential to discriminate between the two matched groups during the pre-conversion period. Results: Subjects who developed SPMS showed accelerated rates of spinal cord atrophy (-2.28 mm 2 /year, standard error (SE) 0.21) before conversion to a SP course compared to their RRMS matches who did not convert to SPMS (-0.74 mm 2 /year, SE 0.21, p<0.0001), with men demonstrating a more rapid decline. Our data suggest that this difference exists at least four years before conversion to SPMS. Measures of brain atrophy and white matter lesions did not discriminate between the groups.
Conclusion:
Upper cervical cord atrophy, as obtained from routine T1-weighted brain MRI, is a strong indicator of impending conversion to SPMS. As cervical atrophy likely reflects neurodegenerative processes, it could be used to identify RRMS patients at risk for secondary progression, assess the role of genetic, epidemiologic and immune variables on MS, and measure the long-term impact of treatment in clinical trials.
The Mitochondrial Innate Immune Sensor, NLRX1, Inhibits Early Stages of CNS Inflammation and Prevents the Onset of Progressive EAE
Dr. Marjan Gharagozloo, PhD, Shaimaa Mahmoud, Camille Simard, Kenzo Yamamoto, Véronique Blais, Jean-Bernard Denault, Louis Gendron, Abdelaziz Amrani and Denis Gris University of Sherbrooke, Sherbrooke, QC, Canada Background: MS is a chronic disease of the CNS, manifested by relapses in the early phase followed by progressive disability in the later phase. Innate immune response plays a critical role in driving both phases; however, the current MS treatments mainly target peripheral immune response with limited effect on CNS inflammation. Therefore, anti-inflammatory molecules expressed by CNS cells can serve as therapeutic targets to prevent the onset and progression of MS. Nlrx1 is a mitochondria-located innate immune sensor that ubiquitously expressed and inhibits NF-κB signaling pathway. We hypothesized that Nlrx1 inhibits CNS inflammation and prevents the onset of spontaneous EAE (spEAE). We generated a new mouse model of MS by crossing Nlrx1 −/− mice with myelin-specific TCR transgenic mice (2D2). The resulting progeny are genetically susceptible to spEAE.
Objectives:
To investigate the role of Nlrx1 in innate immune response and predisposition to EAE. Methods: We characterized the CNS inflammation in healthy and spEAE mice. Furthermore, we evaluated disease progression after transfer of activated myelin-specific T cells into Rag −/− and Nlrx1 −/− Rag −/− mice. The expressions of neurotoxic glia genes were assessed using qPCR. The level of HMGB1 in the tissue was quantified using western blot. The toxic effect of LPS-activated glia on neuroblastoma cells (N2A) and oligodendrocytes (MO3.13) was measured by MTT assay and flow cytometry. Results: Nlrx1 −/− 2D2 mice developed spEAE (54%) with rapid progression of clinical signs from the onset. We observed demyelination and massive infiltration of inflammatory cells into the spinal cord of spEAE mice. In adoptive transfer experiment, Nlrx1 −/− Rag −/− mice developed a significantly higher expression of glial inflammatory markers and EAE score than Rag −/− mice. Interestingly, in asymptomatic Nlrx1 −/− 2D2 mice, we found a subclinical early stage of inflammation and microglia activation, associated with a significant induction of A1 neurotoxic astrocyte genes in the brains. We also observed an increased level of danger signal, HMGB1, in the CNS of journals.sagepub.com/home/msj Multiple Sclerosis Journal 2019; 25: (S1) 3-19 ACTRIMS 25(S1)asymptomatic Nlrx1 −/− 2D2 mice. The conditioned medium of LPS-activated Nlrx1 −/− glia was toxic to N2A and MO3.13 cells. Conclusion: Nlrx1 prevents the generation of inflammatory microglia, neurotoxic astrocytes, and necrotic cell death that trigger the activation of myelin-specific T cells and spEAE. Nlrx1 can be considered as a potential therapeutic target for preventing CNS inflammation in MS.
Objectives: To assess whether biological aging as measured by leukocyte telomere length (LTL) is associated with clinical disability and brain volume in individuals with MS. Methods: Adults with MS or CIS enrolled in the EPIC cohort study at University of California San Francisco were included. LTL was measured on stored baseline DNA samples by quantitative PCR and expressed as the ratio of the abundance of telomere vs. a single copy gene (T/S). Expanded Disability Status Scale (EDSS) and high-resolution 3D T1 weighted brain MRI were performed at baseline and follow-up visits. Associations of baseline LTL with cross-sectional and longitudinal clinical outcomes were assessed using simple and mixed effects linear regression models with random slopes, adjusting for chronological age, sex, HLA-DRB1*15:01 status, and disease duration. A subset of 23 individuals who developed secondary progression during follow-up were matched on age, sex and disease duration to participants who remained with relapsing MS, and they had LTL measured over time. The association of change in LTL with change in EDSS was assessed in these pairs with mixed effects models.
Results: Included were 356 women and 160 men (mean age 43 yrs, median disease duration 6 yrs, median EDSS 1.5 (range 0-7) at baseline). Higher age (p<0.001) and disease duration (p<0.001) were associated with shorter LTL. In analyses adjusted for age, disease duration and sex, for every 1 standard deviation (SD) unit lower LTL, EDSS was 0.25 units higher (95% CI 0.12-0.38, p<0.001) and total brain volume was 6.75 mm 3 lower (0.09-13.41, p=0.047) at baseline. In longitudinal adjusted analyses, those with lower baseline LTL consistently had higher EDSS and lower brain volumes over time. In adjusted analysis of the 23 matched pairs, change in LTL was predictive of change in EDSS over 10 years: for every 1 SD unit decrease in LTL, EDSS was 0.31 units higher (0.07-0.55, p=0.013). Conclusion: Shorter telomere length was associated with disability in both cross-sectional and longitudinal analyses after adjustment for chronological age, suggesting biological aging may contribute to neurological injury in MS. Targeting aging-related mechanisms may be a potential therapeutic strategy. Background: Age-related declining efficacy of immunomodulatory treatments of multiple sclerosis (MS) suggests that while systemic activation of adaptive immunity drives early stages of MS, alternative processes may underlie disability progression in older patients. Pathology identified these alternative processes as aberrant activation of astrocytes and microglia, and subsequent degeneration of oligodendrocytes and neurons. However, we mostly lack biomarkers that could measure central nervous system (CNS) cell-specific intrathecal processes in living subjects. This prevents differentiating pathogenic processes from an epiphenomenon.
Cerebrospinal Fluid Biomarkers Link Toxic Astrogliosis and Microglial Activation to Multiple Sclerosis Severity
Objectives: Therefore, we sought to develop biomarkers of CNS cell-specific processes and link them to disability progression in MS. Methods: In a blinded manner, we measured over 1000 proteins in the cerebrospinal fluid (CSF) of 431 patients with neuroimmunological diseases and healthy volunteers using modified DNA-aptamers (SOMAscan®). We defined CNS cell type-enriched clusters using variable cluster analysis, combined with in vitro modeling. Differences between diagnostic categories were identified in the training cohort (n = 217) and their correlation to disability measures were assessed; results were validated in an independent validation cohort (n = 214). Results: One microglial cluster was significantly elevated in all MS subgroups (relapsing-remitting [RRMS],
primary-[PPMS] and secondary-progressive MS [SPMS]).
In contrast, only progressive-MS subjects had significantly increased neuronal, endothelial, astrocytic and oligodendroglial clusters. Astrocyte cluster 8 (MMP7, SERPINA3, GZMA and CLIC1) and microglial cluster 2 (DSG2 and TNFRSF25) had a significant and reproducible correlation with MS Disease Severity Scale (MS-DSS), suggesting their pathogenic role. In vitro studies demonstrated that proteins of astrocyte cluster 8 are noticeably released upon stimulation with proinflammatory stimuli and overlap with the phenotype of recently described neuro-toxic astrocytes. Conclusion: Microglial activation is present in all stages of MS, while toxic astrogliosis increases with MS duration, concomitantly with neuronal and oligodendroglial degeneration. Microglial activation and toxic astrogliosis likely partake in CNS tissue destruction and enhance MS severity.
Background: Plasma Cells (PC) have been associated with disease pathogenesis, including autoimmune diseases such as Multiple Sclerosis (MS) where they have been found both in the central nervous system (CNS) parenchyma, cerebral spinal fluid and in the meninges. Treatment of relapsing-remitting MS (RRMS) with anti-CD20 antibodies that deplete B cells is followed by rapid and durable suppression of relapses, and prevention of newly formed inflammatory lesions in the CNS. However, this therapy does not target CD20 neg PC. Accordingly, oligoclonal immunoglobulin bands in the CSF of MS patients, a diagnostic hallmark of the disease, are unchanged following anti-CD20 treatment. In contrast to anti-CD20 therapy, treatment with atacicept (TACI-Ig), an agent that neutralizes both APRIL and BAFF, not only reduces circulating B cells but also decreases serum Ab titres, particularly IgM and IgA. Suggesting that some PC can play a regulatory role during MS that it is still unclear.
Objectives: In this study we want to characterize the kinetics, source and function of IgA+ B cells entering the CNS during Experimental Acute Encephalomyelitis (EAE). Considering that mucosal surfaces are the major site for generating IgA responses, we hypothesized that IgA+ PB/ PC may be liberated from the mucosae prior to entering into the CNS in response to CNS inflammation Methods: We induce EAE with MOG Background: Precision medicine is a medical model that proposes the customization of healthcare, with medical decisions, treatments, practices, or products that are tailored to the individual patient. This is different to personalized medicine, which separates people into different groups and population health that targets whole populations.
Objectives: (1) To understand the differences between, and have working definitions of, population health, personalised medicine and precision medicine. (2) To use baseline prognostic factors to select a treatment strategy for individual patients. (3) To use biomarkers to make clinical decisions that impact individual patients in relation to the optimisation and derisking of disease-modifying therapies. Methods: Not applicable as this is an invited talk. Results: A baseline risk calculator using a simple ranking scale will be used to help categorise patients into three prognostic groups. The prognosis can then be used to help select a suitable treatment strategy for individual patients. Several biomarkers will be discussed including baseline screening, treatment response, treatment non-response and pharmacovigilance markers to optimise and derisk therapies for individual patients.
Conclusion:
It is clear that a large number of biomarkers have been introduced into clinical practice that can be applied at the individual patient level to optimise clinical outcomes and to derisk treatments as much as possible. Multiple sclerosis exhibits a well-documented increased incidence in individuals with respective family history, i.e. is a heritable disease. Family and twin studies have quantified the overall heritable contribution, however none of these study designs have resulted in reliable genetic associations. The last decade, genome-wide associations studies (GWAS) have enabled the agnostic interrogation of the whole genome at large scale. To date, over 200 genetic associations have been described at the strict level of genome-wide significance (p-value < 5x10 -8 ), by analyzing more than 45,000 MS subjects and 65,000 controls. These associations highlight a complex interplay of genetic variation that contribute to MS susceptibility, including variants in the major histocompatibility complex (MHC) region and the rest of the genome. Our current understanding of MS genetics can explain up to half of the disease's heritability, raising the important question of whether this is enough information to leverage toward improve diagnosis in MS. Parallel advancements in technologies that allow the characterization of the full transcriptome down to the single-cell level have enabled the generation of an unprecedented wealth of information. Transcriptional changes of putative causal cells could be utilized to identify early signs of disease onset. These recent findings in genetics and genomics, coupled with new technologies and deeplyphenotyped cohorts have the potential to improve the diagnosis of MS. A complex multifactorial signature that can change dynamically with new information and applied at different clinical settings seems to be the most probable way that genetics and genomics can support early and more accurate diagnosis in MS. In this presentation, we summarize the current status of genetic and genomics studies in MS and we discuss translational concepts and efforts toward diagnosis.
Precision Medicine in the MS
Immune profiling in demyelinating disease: setting new goals for precision diagnosis and treatment Jeffrey L. Bennett, MD, PhD
University of Colorado
Immune profiling has systematically advanced our understanding of the pathologic processes driving human demyelinating disorders. Serologic, flow cytometric, and molecular characterization of the adaptive and innate immune responses in multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), myelin oligodendrocyte glycoprotein (MOG) encephalomyelitis, and their animal models have successfully identified disease-associated antigenic targets, pathogenic autoantibodies, and immune cell subsets that have enhanced our ability to diagnose and treat patients with demyelinating diseases.
Serologic assays for the detection of aquaporin-4 (AQP4) and MOG autoantibodies have already entered routine clinical practice and allow clinicians to diagnose and treat NMOSD and MOG patients with greater accuracy. New antigenic targets, such as glial fibrillary acidic protein (GFAP), are poised to expand the current diagnostic landscape; while other markers, such as glucose regulated protein 78 (GRP-78) autoantibodies and chitinase 3-like (CHIL) proteins, are likely to open novel avenues for monitoring disease activity. Antigen-specific treatments designed to prevent tissue injury or induce disease tolerance are soon to enter the clinical arena and offer new opportunities for precision therapy.
Recent research advances have allowed the detailed characterization of immune cell subsets based on cell-surface markers, cytokine expression, T-and B cell receptors, and RNA and protein expression. In MS and NMOSD patients, alterations in the balance of pro-inflammatory and regulatory T-and B cell subsets are now being linked to disease activity and therapeutic response. Furthermore, clonal B cell populations, identified by next generation sequencing, are being used to develop disease-specific molecular diagnostic signatures. With the application of multi-parametric flow cytometry, mass cytometry, proteomics, and single cell analytics, new cell populations and interactions are being discovered within the complex immune network driving demyelinating pathology. Moving forward, these advanced analytics are primed to identify novel therapeutic pathways and next generation precision diagnostic and prognostic assays.
Classification and Prognostication using MS Severity Score
Dr. Ilya Kister, MD NYU, New York, NY Background: Multiple Sclerosis Severity Score, MSSS (Roxbourgh et al., 2005) , and Patient-derived Multiple Sclerosis Severity Score, P-MSSS (Kister et al. 2013) , are mean ranks, expressed as deciles, of disability scores among patients with similar disease duration. Severity score can be conceptualized as an approximation of the prevalence (maximum rank) of disability scores in the reference cohort of patients with similar disease duration. For example, a patient with a severity score of 1.7 is as much or more disabled than approximately 17% of patients with the same disease duration.
Objectives: To describe the various application of MS severity score for clinical research and practice. Methods: Review of literature Results: Severity score could be used as a basis of severity-based classification of MS, as proposed by Dr. Joseph Herbert, who defined 'benign MS' as (P)MSSS<0.45, and 'aggressive MS' as (P)MSSS>8.3, and introduced a six-tiered severity classification that allows clinicians to easily communicate disease severity in MS (Charlson et al., 2017) . Severity score could also be used in the design of clinical trials -both to formulate inclusion criteria and as an outcome measure, and in clinical research -to compare disease severity in subpopulations of interest (Ventura et al., 2017) , track disease progression of a patient cohort (Kister et al., 2011) , and assess the effect of a specific variable (ie, body mass index) on disease severity (Richter, et al 2017) . Of special interest in the application of severity score to prognosticating the disease course. Severity score has been shown in several studies to remain relatively constant at the cohort level, though not on the individual level (Roxbourgh et al, 2005; Daumer et al., 2009; Hughes et al, 2012 ). Yet, baseline severity score was shown in multivariable regression analysis to be by far the most robust predictor of final disease severity as compared to other previously identified predictors of long-term outcome, such as male sex or progressive disease subtype (Kister et al., 2018) . Conclusion: Severity score has proven its utility for a number for clinical investigations in MS. It is the basis for severity-based classification of MS and should be incorporated into prognostic studies of MS. Severity score is currently being used for improving models that predict disease responsiveness to disease-modifying therapies. Objectives: To present recent data for new MRI methods that may aid in the diagnosis of MS Methods: Presentation Results: Several MRI methods that reflect different pathological changes that may be highly specific to MS have shown promise as potential diagnostic biomarkers. These include the evaluation for "central veins", volumetric assessment of deep gray matter structures, quantification of cortical myelin, and the evaluation of peri-lesional and lesion-specific morphological characteristics. Conclusion: Emerging MRI methods may yield objective and automated screening tools to differentiate MS from other disorders. Prospective multicenter studies are necessary to validate promising cross-sectional data. An approach combining several methods and/or utilizing machine learning may yield thresholds with optimal specificity and sensitivity for MS.
Cutting Edge Developments
Mass Spec Imaging of MS Lesion Dr. Jennifer Gommerman, PhD University of Toronto, Toronto, ON, Canada Background: While subpial cortical injury has emerged as an important component of progressive disease in multiple sclerosis (MS), the mechanisms that mediate pathogenesis in this compartment remain unclear. Subpial pathology may be driven by an immune response, constrained to the inflamed meninges. However, we know little about the types of immune cells that populate the meninges, their soluble by-products and the stromal cells that support their localization to this location. A comprehensive picture of meningeal infiltrates adjacent to subpial lesions is required to understand the mechanism(s) driving subpial pathology, and is critical to guiding development of therapies for progressive MS.
Objectives: To determine if meningeal inflammation is present in the MS brain using tissues from the Netherlands Brain Bank, and to pilot the use of Imaging Mass Cytometry (IMC) for multi-parameter analysis of MS tissues. Methods: To begin to address these gaps, we have examined post-mortem MS cortical brain tissue from the Netherlands Brain Bank by standard histology. To extend our immunohistochenistry observations, we have adopted IMC, a novel multi-parameter technique that uses CyTOF technology to reconstruct the staining pattern of metal-conjugated antibodies bound to a single slide-mounted tissue section. Results: In a pilot study, using standard immunohistochemistry on this tissue, we have shown enrichment of CD3+ T and CD20+ B cells in the meninges of a subset of progressive MS patients. Only those patients with "active/ chronic active" white matter lesions harboured meningeal immune cells, and these overlaid areas of subpial cortical demyelination. We then turned to IMC in order to better characterize immune cells in the MS brain. In a pilot experiment, we stained "active/chronic-active" lesions from a single MS patient with multiple metal-tagged antibodies and identified various brain-resident immune cells, endothelial cells and glial cells as well as extracellular matrix proteins and secreted proteins, all on a single tissue section via IMC. Conclusion: Meningeal inflammation is observed in a subset of progressive MS patients. The emerging IMC technique will prove useful for further characterization of meningeal-resident cells associated with areas of subpial cortical injury in this subset of patients.
Characterization of MS brain lesions using flow cytometry and histochemistry

Tess Dhaeze Universite de Montreal
Background: Detailed characterization of immune cells in brain lesions of persons living with multiple sclerosis (MS) is commonly performed by immunohistofluorescence (IHF). Since this technique only allows phenotyping of immune cells with 3-4 markers, the need for other techniques to further explore the profile of these infiltrating cells is high.
Objectives: To provide a method to assess both the phenotype of infiltrating immune cells (with flow cytometry) and the type of lesion (with histochemistry) within a single MS brain lesion. Methods: MS brain tissue (n=2-3) with a short-postmortem delay is cut into slides. Demyelinated areas (lesions) or normal appearing tissue are cut out from grey and white matter. One third of the lesion/tissue piece is directly frozen for lesion characterization (pre-active, active, chronic inactive and cortical lesions) by hematoxylin and eosin (H&E), luxol fast blue (LFB) and Oil red O staining. The rest is processed for flow cytometric analysis. For this, each lesion is cut separately into very fine pieces and treated with Collagenase and DNase. Next, it is passed through a 100 µM and 70 µM membrane. The suspension is then loaded onto a 37% percoll for immune cell isolation. To further purify the cell suspension, red blood cells are removed by positive magnetic bead isolation. The obtained immune cells are then processed for flow cytometry. Results: Preliminary results show that we can detect a high number of T lymphocytes (CD3, CD4 and CD8) with an overall higher CD8/CD4 ratio. Furthermore, we could characterize their adhesion molecule profile (MCAM, α8 integrin, ALCAM, CD6, ICAM) together with specific subsets that are overrepresented (CCR7 and CD45RA). A smaller number of other infiltrating immune cells were also identified such as dendritic cells (CD11c) and B cells (CD19). This information is then combined with the data obtained from histochemistry to see in what lesion type these cells are present.
Conclusion:
Our technique allows to characterize immune cells found in one specific MS lesion using both flow cytometry and histochemistry to define the type of immune cells (T and B cells, DC, macrophages/microglia) that are present within a specific lesion type (pre-active, active, chronic inactive, cortical) to gain insight into specific immune cell infiltration based on the type of lesion. Astrocytes play important roles in the central nervous system (CNS) during health and disease. Thus, the identification of factors that regulate astrocyte activity may shed light on CNS physiology and guide new therapies for human neurologic disorders. In this presentation we will discuss mechanisms used by astrocytes to control CNS inflammation. In addition, we will discuss molecular pathways involved in the control of astrocyte function. For example, we recently found that microbial metabolites limit astrocyte pathogenic activities in the context of CNS inflammation, while environmental factors can boost these disease promoting activities. Finally, we will review ongoing efforts on the characterization of astrocyte heterogeneity in MS. 
Background:
The spinal cord is commonly affected in multiple sclerosis (MS) patients and is an important contributor to physical disability. Myelin water imaging (MWI) provides a quantitative in vivo measurement of myelin content, termed myelin water fraction (MWF). MWF mean (myelin content) and standard deviation (SD; myelin content heterogeneity) can be used to study myelin abnormality.
Objectives: (1) To assess myelin damage in the cervical cord white matter (WM) in relapsing and progressive MS compared to healthy controls (HC). (2) To evaluate the correlation between MWF and clinical disability as measured by timed 25-foot walk (T25W) and Expanded Disability Status Scale (EDSS). Methods: MWI data was acquired from 14 relapsing MS (mean age 42y (range 26-57y), median EDSS 2.25 (1.0-4.0)), 18 progressive MS (mean age 58y (48-65y), median EDSS 4.0 (2.0-8.5)) and 14 HC (mean age 40y (22-63y)) using a gradient and spin echo (GRASE) sequence (reconstructed at 2.5 mm thickness, 16 slices) on a 3T Philips scanner. Mann Whitney-U test compared the MWF mean and SD at the C2/3 level in the global cervical cord and WM, dorsal column, lateral funiculi and ventral funiculi, which were registered and segmented using the Spinal Cord Toolbox, between cohorts. Spearman's rho (r) was used to correlate MWF with T25W and EDSS scores in MS cohorts. Results: Mean MWF in the dorsal column was significantly lower in progressive MS compared to HC (p=0.05). There was a trend towards lower mean MWF in both MS cohorts compared to HC in global cervical cord, global WM and lateral funiculi. No significant correlation was found between mean MWF and T25W or EDSS. MWF SD was significantly higher in progressive MS compared to HC in all regions of interest (p=0.01 to 0.04). MWF SD was significantly correlated with EDSS in the global cervical cord (r=0.64, p=0.01), global WM (r=0.63, p=0.01) and lateral funiculi (r=0.75, p<0.001) for progressive MS. Conclusion: Lower myelin content, higher myelin content heterogeneity and moderate to strong correlations between myelin content heterogeneity and EDSS score in the cervical cord in progressive MS suggest that myelin damage may, in part, contribute to disability in progressive MS. Myelin content heterogeneity detect more subtle alteration in cervical cord myelin, providing a more sensitive tool than mean MWF alone. Objectives: To determine the association between MSPT components, patient-reported outcomes (PROs), and quantitative MRI metrics in a large clinical cohort. Methods: MSPT, PROs, and quantitative MRI data were collected at a single site. Brain MRIs obtained within 90 days of a clinical encounter during which MSPT and PROs were collected were analyzed via a fully-automated method to calculate T2 lesion volume (T2LV), normalized whole brain volume (whole brain fraction, WBF), thalamic volume (TV), and cross sectional upper cervical spinal cord area (SCA). Spearman correlations and linear regression models were used to correlate MSPT components with PROs and MRI metrics (significance level set at p<0.001). Results: The study population included 976 patients (mean age 47.7 ± 11.4 years, 71.8% female). There were moderate correlations between MSPT and PROs, the strongest being Patient Determined Disease Steps (PDDS) (rho=0.64) and Quality of Life in Neurological Disorders (Neuro-QoL) lower extremity (-0.65) with WST, and Neuro-QoL upper extremity (-0.53), Neuro-QoL lower extremity (-0.54), and PDDS (0.53) with MDT (p<0.001 for all). Linear regression identified T2LV and WBF as MRI predictors for PST (R 2 =0.46), TV and CA for CST (R 2 =0.30), T2LV and WBF for MDT (R 2 =0.37), and T2LV and CA for WST (R 2 =0.39). Conclusion: Impaired performance on MSPT was associated with worse physical disability-related PROs and MRI metrics, but the strongest predictors of neuroperformance test components varied. These results illustrate the feasibility and relevance of the MSPT, PROs, and advanced MRI measures in clinical practice. Future efforts will focus on validation and incorporation of quantitative MRI assessment into routine MS clinical care and longitudinal assessments. NINDS, NIH, Bethesda, MD, 2 Siemens Medical Solutions, Bethesda, MD, 3 Siemens Medical Solutions, Burlington, MA, 4 
Comprehensive Assessments in Clinic Using
NIMH, NIH, Bethesda, MD
Background: High-spatial-resolution susceptibility-weighted imaging of the brain anatomy has recently gained a lot of attention for investigating novel biomarkers in multiple sclerosis (MS) such as the 'central vein sign' which may aid with MS diagnosis and 'phase rims' which may predict the outcome of new MS lesions. To allow rapid susceptibility-based imaging of the entire brain at submillimeter resolution, we have developed a volumetric (3D) segmented echo-planar-imaging (EPI) sequence.
Objectives:
In this study, we aimed at demonstrating the feasibility of an accelerated version of our prototype sequence using parallel imaging which allows acquiring whole brain images at 0.65 mm isotropic resolution in approximatively 3 minutes. Methods: Generalized Auto-calibrating Partially Parallel Acquisition (GRAPPA) was implemented on a previously introduced 3D-EPI prototype sequence. The accelerated prototype sequence was tested on a 3T scanner equipped with a 32-channel RF-receive head coil. A high-resolution journals.sagepub.com/home/msj Multiple Sclerosis Journal 2019; 25: (S1) 3-19 ACTRIMS 25(S1) 13 (0.65 mm isotropic) protocol was setup for imaging the small parenchymal veins running through MS white matter lesions. Main parameters were as follow: matrix = 384 x 312 x 256, TR = 64 ms, TE = 35 ms, FA = 10, EPI factor = 15, R = 2, scan time = 3 min 14 sec. Three subjects with MS were scanned to assess the feasibility of this clinicallycompatible protocol for detecting central veins and phase rims. The same sequence was repeated without acceleration (no GRAPPA, scan time = 5 min 40 sec) to compare image quality. Both magnitude (T2*-weighted) and phase images were collected. Phase images were further post-processed for quantitative susceptibility mapping (QSM).
Results: High-resolution T2*-weighted images of the whole brain were collected in ~ 3 minutes using the 3D-EPI prototype sequence with parallel imaging (GRAPPA). White matter lesions and small medullary veins were readily detected on T2* contrast. Some of the white matter lesions displayed a paramagnetic rim on the corresponding phase and QSM images. When compared with the nonaccelerated images, the loss in SNR due to the total acceleration factor of 2 only minimally affected the overall image quality.
Conclusion:
In this pilot study, we demonstrated the feasibility of a two-fold accelerated 3DEPI prototype sequence which acquires whole-brain images at 0.65 mm isotropic resolution in approximately 3 minutes. This enables the routine acquisition of high-resolution isotropic MR susceptibility brain imaging in patients with MS.
Background: Radiomics is the extraction of quantitative imaging features from digital medical images. These features can be utilized to build machine learning models that predict important clinical outcomes of disease. Multiple sclerosis (MS) patients routinely obtain magnetic resonance imaging (MRI) that can be mined via radiomics to construct clinically relevant predictive models.
Objectives:
Compare machine learning models constructed from radiomic features with models constructed from clinical data and lesion volumes to predict disability and treatment response in relapsing remitting (RR) MS. Methods: 92 RRMS patients from 3 separate centers from the CombiRx trial were selected for the analysis. Median dichotomized baseline Expanded Disability Status Scale (EDSS), baseline Paced Auditory Serial Addition Test (PASAT) dichotomized by a score of 35, and Disease Activity Free Status (DAFS) after 36 months were used as output variables for the machine learning classification models. Radiomic features related to shape, intensity, and texture were extracted from MS lesion regions of interest on entry T1 and FLAIR MRI images and used as input variables. Supervised machine learning models were constructed from the radiomic features to predict each output variable and evaluated with leave one out cross validation (LOOCV). Synthetic minority oversampling was utilized to balance class distributions of output variables. Models were also constructed from baseline clinical data and lesion volume for comparison.
Results: Predictive performance of models was assessed using LOOCV area under the receiver operating characteristic curve (AUC). Radiomics-based machine learning models achieved AUC scores of 0.83, 0.75, and 0.70 for EDSS, PASAT, and DAFS respectively. Corresponding clinical models achieved AUC scores of 0.48, 0.43, and 0.40 for EDSS, PASAT, and DAFS respectively. Models based on lesion volumes achieved AUC scores of 0.55, 0.66, and 0.43 for EDSS, PASAT, and DAFS respectively. Conclusion: Machine learning models constructed from radiomic features achieved better predictive performance than models based on clinical features or lesion volume for measures of disability and treatment response. This multicenter approach lends credence to the application of radiomics for the prediction of clinically relevant outcomes in RRMS. Validation of our findings against the full CombiRx dataset is now required.
inflammation are still poorly characterized. Recent neuropathological findings reported that high levels of inflammation, diffuse and/or structured in tertiary lymphoid organ-like (TLO), in the meninges of a subgroup of MS patients positively correlate with extensive, active subpial GM damage and more rapid clinical progression. The cortical injury found associated with meningeal infiltrates occurs through a gradient "surface-in" of neuronal and glia alterations, elevated in the external cortical layers close to the pia and decreasing towards the inner ones close to white matter.
Objectives: Since meningeal infiltrates and lymphoidlike structures in the subarachnoid space, are considered as the major contributors in releasing inflammatory/cytotoxic mediators in the cerebrospinal fluid (CSF), it is reasonable to hypothesize that intrathecal (meninges and CSF) inflammation might have a major role in mediating cortical damage and rapid progressive evolution of the disease. Methods: By combining neuropathology, CSF molecular analysis and advances 3T MRI imaging, a comprehensive analysis of potential correlation between intrathecal inflammation and cortical damage has been investigated both in post-mortem MS patients and in naive MS patients at time of diagnosis. Results: Combined analysis of post-mortem MS meningeal infiltrates and paired CSF samples has shown that meningeal infiltrates are the main source of inflammatory factors diffusing through the CSF. A specific CSF inflammatory profile, including high protein levels of CXCL13, IFNγ, TNF, CXCL12, IL6, IL10 and LIGHT, was demonstrated able to predict up to 89% of the variance in GM number/volume in a subgroup of either in vivo MS patients at time of diagnosis or in post-mortem MS populations with increased meningeal inflammation. Conclusion: A specific combined CSF and MRI pattern might represent a useful surrogate marker of meningeal inflammation able to stratify MS patients according to the level of intrathecal inflammation and cortical lesion load at diagnosis. Background: Corneal confocal microscopy is a non-invasive ophthalmic imaging modality, which was used predominantly in the diagnosis and management of corneal disease. However, over the last 20 years it has come to the forefront as a rapid, non-invasive imaging biomarker for neurodegeneration.
Retinal imaging for MS diagnosis and monitoring
Objectives: To share data showing that quantification of corneal nerve morphology using corneal confocal microscopy is a reliable and reproducible method to quantify corneal nerve morphology. Methods: Corneal confocal microscopy to quantify corneal nerves. Results: Changes in corneal nerve morphology precede or relate to clinical manifestations of peripheral and central neurodegenerative disease. Moreover, in clinical intervention trials, corneal nerve regeneration occurs
